Day One Biopharmaceuticals, Inc vs UnitedHealth Group Incorporated — Stock Comparison
Q·Score Breakdown
4.5
Bearish
Overall
6.3
Neutral
Quality
Health
Growth
Valuation
Sentiment
DAWN
Clean balance sheet with low leverage (0.0× debt-to-equity).
⚠ currently unprofitable (-68% margin).
UNH
82% of 28 covering analysts have a positive rating.
⚠ limited growth momentum.
Analyst Consensus
HOLD
Target $21.50 (-0.1%)
6 analysts
BUY
Target $387.27 (+5.0%)
26 analysts
Fundamentals
DAWN
UNH
—
Trailing P/E
27.9×
-112.4×
Forward P/E
17.8×
-67.8%
Profit Margin
2.7%
89.1%
Gross Margin
18.8%
-22.7%
ROE
12.2%
83.9%
Revenue Growth
2.0%
—
Earnings Growth
0.7%
-1.75
Beta
0.41
—
Price / Book
—
$2.2B
Market Cap
$334.9B
$6 – $22
52-Week Range
$235 – $410
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →